Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to DO2004000815ApriorityCriticalpatent/DOP2004000815A/en
Publication of DOP2004000815ApublicationCriticalpatent/DOP2004000815A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
La invención se refiere a un método para tratar el virus de la inmunodeficiencia humana (HIV) en un mamífero, que comprende administrar a un mamífero que lo necesite una cantidad terapéuticamente eficaz de una composición farmacéutica, en el que el nelfinavir se administra con alimentos.The invention relates to a method for treating human immunodeficiency virus (HIV) in a mammal, which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition, in which nelfinavir is administered with food.
DO2004000815A2004-02-062004-02-06
TREATMENT METHOD WITH NELFINAVIR
DOP2004000815A
(en)
DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PREPARATION
A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process.
ORAL DOSING UNIT INCLUDING AN ANTAGONIST AGENT FOR PUMPS OF PROTONS AND EXCIPIENTS OF BASIC CHARACTER; PROCEDURE FOR PREPARATION, USEFUL TO TREAT DISEASES CAUSED BY AN INCREASED SECRETION OF GASTRIC ACIDS.